Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
出版年份 2017 全文链接
标题
Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
作者
关键词
-
出版物
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume 17, Issue 12, Pages 1089-1096
出版商
Informa UK Limited
发表日期
2017-10-23
DOI
10.1080/14737159.2017.1395701
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer
- (2017) Emil Christensen et al. EUROPEAN UROLOGY
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
- (2017) Christopher Abbosh et al. NATURE
- Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs
- (2017) Yan-juan Zhu et al. Oncotarget
- Using Multigene Tests to Select Treatment for Early-Stage Breast Cancer
- (2017) Rodrigo Goncalves et al. Journal of the National Comprehensive Cancer Network
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases
- (2016) Jing Zhao et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
- (2016) J. C. Thompson et al. CLINICAL CANCER RESEARCH
- Comparison of liquid-based preparation and conventional smear of fine-needle aspiration cytology of lymph node
- (2016) Pranab Dey et al. Journal of Cytology
- Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial
- (2016) Qing Zhou et al. Journal of Hematology & Oncology
- 147P: Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non-small-cell lung cancer in Spain: ASSESS study
- (2016) E. Arriola et al. Journal of Thoracic Oncology
- Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
- (2016) Yang-Si Li et al. Journal of Thoracic Oncology
- Scientific Advances in Lung Cancer 2015
- (2016) Anne S. Tsao et al. Journal of Thoracic Oncology
- A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma
- (2016) Karen L. Reckamp et al. Journal of Thoracic Oncology
- Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations
- (2016) Hua-Jie Dong et al. LUNG CANCER
- The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: A systematic review with meta-analysis
- (2016) Tao Jiang et al. LUNG CANCER
- Integrated digital error suppression for improved detection of circulating tumor DNA
- (2016) Aaron M Newman et al. NATURE BIOTECHNOLOGY
- Circulating Tumor Cells Identify Early Recurrence in Patients with Non-Small Cell Lung Cancer Undergoing Radical Resection
- (2016) Clara Bayarri-Lara et al. PLoS One
- Noninvasive monitoring of the genetic evolution of EGFR-mutant non-small-cell lung cancer by analyzing circulating tumor DNA during combination chemotherapy with gefitinib and pemetrexed or S-1
- (2016) Yoshiro Nakahara et al. OncoTargets and Therapy
- Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
- (2016) Jacob J. Chabon et al. Nature Communications
- Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA
- (2016) Marzia Del Re et al. Oncotarget
- Detection of the T790M mutation of EGFR in plasma of advanced non–small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)
- (2016) Takayuki Takahama et al. Oncotarget
- Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
- (2016) D. Zheng et al. Scientific Reports
- Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
- (2015) T. Mok et al. CLINICAL CANCER RESEARCH
- Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer
- (2015) Wei Sun et al. Journal of Hematology & Oncology
- Lung Cancer Screening, Version 1.2015
- (2015) Douglas E. Wood et al. Journal of the National Comprehensive Cancer Network
- Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer
- (2015) Xiaoxia Chen et al. Journal of Thoracic Oncology
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- (2015) Kenneth S Thress et al. NATURE MEDICINE
- Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
- (2015) Isaac Garcia-Murillas et al. Science Translational Medicine
- Association ofEGFRL858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial
- (2015) Niki Karachaliou et al. JAMA Oncology
- Liquid Biopsies: Genotyping Circulating Tumor DNA
- (2014) Luis A. Diaz et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
- (2014) Jean-Yves Douillard et al. Journal of Thoracic Oncology
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Tumour heterogeneity in the clinic
- (2013) Philippe L. Bedard et al. NATURE
- The causes and consequences of genetic heterogeneity in cancer evolution
- (2013) Rebecca A. Burrell et al. NATURE
- Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
- (2013) Muhammed Murtaza et al. NATURE
- Liquid biopsy: monitoring cancer-genetics in the blood
- (2013) Emily Crowley et al. Nature Reviews Clinical Oncology
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
- (2012) T. Forshew et al. Science Translational Medicine
- Potential clinical significance of plasma-based KRAS mutation analysis using the COLD-PCR/TaqMan® -MGB probe genotyping method
- (2012) PEIJIA LIU et al. Experimental and Therapeutic Medicine
- Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer
- (2011) Youwei Zhang et al. CANCER LETTERS
- Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas
- (2011) K. Taniguchi et al. CLINICAL CANCER RESEARCH
- Genomic analysis of circulating cell-free DNA infers breast cancer dormancy
- (2011) J. A. Shaw et al. GENOME RESEARCH
- Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer
- (2011) Rafael Sirera et al. Journal of Thoracic Oncology
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Counting absolute numbers of molecules using unique molecular identifiers
- (2011) Teemu Kivioja et al. NATURE METHODS
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer
- (2010) Ruth E. Board et al. BREAST CANCER RESEARCH AND TREATMENT
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of Mutated K-rasDNA in Urine, Plasma, and Serum of Patients with Colorectal Carcinoma or Adenomatous Polyps
- (2009) Ying-Hsiu Su et al. Annals of the New York Academy of Sciences
- Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non-Small Cell Lung Cancer Patients
- (2009) T. K.F. Yung et al. CLINICAL CANCER RESEARCH
- Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: A meta-analysis
- (2009) Ruifeng Zhang et al. LUNG CANCER
- Circulating mutant DNA to assess tumor dynamics
- (2008) Frank Diehl et al. NATURE MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now